Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
just putting 2 + 2 together here: ( I may be getting 5, but he was a big investor here a few years ago)
Myles McNulty
@MylesMcNulty
Began rebuilding in an old favourite. IMO, its SP is due a parabolic run. This takes into account the quality of its ops, the favourable dynamics of its industry, and the market's current favour to the wider sector. Will provide research when finished buying.
read this and the other Myles thread from yesterday. Christ there are some cynical ********s on here. Sure Myles is gonna look after number one but he was telling anyone that would listen that Avacta was the goose that would lay the golden egg back in 2018 before 99% of you had heard of Avacta and none of us had heard of Covid 19.
Thanks to him, I found myself with a sizeable number of shares in Avacta when the covid test news RNS came out at a sub 30p average. (gone up since). And of course he isnt going to come on here and give us his rationale for buying even more, before he has finished buying more!
https://twitter.com/Tweet_trader01/status/1302649243891568640
christ i might actually break even soon at this rate
very possible - but it does make me wonder who writes these RNSs - and whether they read them before they issue them. the vagueness and the way they leave things open to misintepretation is not clever.
watching - i have done my research, just seeking others opinions.
late to the party here - bought some yesterday at 1.03 and just topped up at .93
realistic views on where this might go? (stupid question i know!)
we all saw the evidence - he tweeted some email or letter from himself and forgot to remove his real name.
we have all been diluted (!) but as of August last year:
Tue, 13th Aug 2019 11:16
RNS Number : 8771I
N4 Pharma PLC
13 August 2019
13 August 2019
N4 Pharma Plc
("N4 Pharma" or the "Company")
Holdings in Company
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing NuvecĀ®, a novel delivery system for vaccines and cancer treatments, announces that it has been notified that, following a purchase of 112,258 ordinary shares of 0.4p each in the company ("Ordinary Shares") earlier today, Mr David Farrier is now beneficially interested in 12,175,510 Ordinary Shares, representing 12.0 per cent. of the Company's issued share capital.